Journal
Haematologica
Publication Date
7-1-2024
Volume
109
Issue
7
First Page
2177
Last Page
2185
Document Type
Open Access Publication
DOI
10.3324/haematol.2023.283737
Rights and Permissions
Maurer MJ, Casulo C, Larson MC, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan JR, Link BK, Flowers CR. Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma. Haematologica. 2024 Jul 1;109(7):2177-2185. doi: 10.3324/haematol.2023.283737. ©2024 Ferrata Storti Foundation Published under a CC BY-NC license.
Recommended Citation
Maurer, Matthew J.; Kahl, Brad S.; and et al., "Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma." Haematologica. 109, 7. 2177 - 2185. (2024).
https://digitalcommons.wustl.edu/oa_4/3970
Additional Links
Supplemental material is available for this article at publisher site.
